- Trials with a EudraCT protocol (44,359)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44,359 result(s) found.
Displaying page 12 of 2,218.
EudraCT Number: 2017-000994-35 | Sponsor Protocol Number: 06032017 | Start Date*: 2018-08-02 | |||||||||||
Sponsor Name:Hospital General Universitario de Alicante | |||||||||||||
Full Title: Study of tolerability of iron liposome compared to ferrous sulphate in pregnant women with iron deficiency anemia. | |||||||||||||
Medical condition: Iron deficiency anaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005510-34 | Sponsor Protocol Number: MMV_DSM265_14_01 | Start Date*: 2015-09-30 | |||||||||||
Sponsor Name:Medicines for Malaria Venture | |||||||||||||
Full Title: Evaluation of the prophylactic antimalarial activity of a single dose of DSM265 in non-immune healthy adult volunteers by controlled human malaria infection with PfSPZ Challenge | |||||||||||||
Medical condition: Healthy volunteers; controlled human malaria infection with PfSPZ | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000727-25 | Sponsor Protocol Number: 47582 | Start Date*: 2017-03-28 |
Sponsor Name:Isala Klinieken | ||
Full Title: The effect of ARTISS on latissimus dorsi donor site seroma formation after breast reconstruction: a randomised controlled trial. | ||
Medical condition: The aim of this study is to investigate the effect of the fibrin sealant ARTISS compared with our standard care on total volume of donor site seroma after harvesting a LD in immediate breast recons... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002955-85 | Sponsor Protocol Number: AVICCI001 | Start Date*: 2016-01-21 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: A feasibility study to assess the effects of AntiretroViral Intensification with Cenicriviroc for the management of HIV-associated Cognitive Impairment. The AVICCI study | |||||||||||||
Medical condition: Human Immunodeficiency Virus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002729-39 | Sponsor Protocol Number: C-07-40 | Start Date*: 2017-11-07 | |||||||||||
Sponsor Name:Alcon Research Ltd | |||||||||||||
Full Title: An Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5% for the Treatment of Bacterial Conjunctivitis in the USA | |||||||||||||
Medical condition: Bacterial conjunctivitis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003426-89 | Sponsor Protocol Number: E2020-J081-345 | Start Date*: 2018-10-18 |
Sponsor Name:Eisai Co., Ltd. (Japan) | ||
Full Title: A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disable... | ||
Medical condition: Down syndrome, regression symptoms and disabled activities of daily living | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-000454-22 | Sponsor Protocol Number: CCR4825 | Start Date*: 2019-02-01 |
Sponsor Name:The Royal Marsden NHS Foundation Trust | ||
Full Title: A translational phase II study of single agent Olaparib in the treatment of advanced oesophagogastric cancer | ||
Medical condition: Advanced Oesophago-gastric cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002516-27 | Sponsor Protocol Number: P121006 | Start Date*: 2014-03-06 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004901-18 | Sponsor Protocol Number: LAM107844 | Start Date*: 2016-08-03 |
Sponsor Name:GlaxoSmithKline Research & Development | ||
Full Title: Clinical Evaluation of lamotrigine in Epilepsy | ||
Medical condition: Epilepsy | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-004870-14 | Sponsor Protocol Number: LOC114220 | Start Date*: 2016-08-03 |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: A multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study to determine the efficacy and safety of nebulized fluticasone propionate 1mg twice daily compared with... | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-004888-37 | Sponsor Protocol Number: FFR111158 | Start Date*: 2016-08-03 |
Sponsor Name:GlaxoSmithKline Research and Development Ltd | ||
Full Title: A Pilot, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Once-daily Intranasal Administration of Fluticasone Furoate Nasal Spr... | ||
Medical condition: Irritant (non-allergic) rhinitis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-000071-90 | Sponsor Protocol Number: AGO/2017/002 | Start Date*: 2017-03-15 |
Sponsor Name:Ghent University Hospital | ||
Full Title: Effect of sevoflurane and propofol on hepato-splanchnic pressure and flow during hepatobiliary surgery. | ||
Medical condition: patients scheduled for hepato-biliary surgery. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000251-74 | Sponsor Protocol Number: SFY10718 | Start Date*: 2017-03-20 | |||||||||||
Sponsor Name:Sanofi | |||||||||||||
Full Title: An open-label, uncontrolled 4-week study to assess the safety, efficacy and pharmacokinetics of Allegra® (dry syrup formulation) 15 mg or 30 mg twice daily in pediatric patients with atopic dermat... | |||||||||||||
Medical condition: Atopic dermatitis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002876-26 | Sponsor Protocol Number: 2017-002876-26 | Start Date*: 2018-10-19 | |||||||||||
Sponsor Name:South Tees Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Telomerase ACTivator to reverse Immunosenescence in Acute Coronary Syndrome: a double-blind, phase II, pilot randomised controlled trial (TACTIC) | |||||||||||||
Medical condition: Immunosenescence in patients who have had an acute coronary syndrome diagnosed within the last 6 months. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003736-21 | Sponsor Protocol Number: ACE-LY-110 | Start Date*: 2017-06-07 | ||||||||||||||||
Sponsor Name:Acerta Pharma BV | ||||||||||||||||||
Full Title: A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects with Relapsed/Refractory B-cell Malignancies | ||||||||||||||||||
Medical condition: Part 1: De novo Diffuse large B-cell lymphoma (DLBCL), Transformed DLBCL and Richter syndrome (RS). Part 2: De novo Germinal center B-cell (GCB) DLBCL and De novo non-GCB DLBCL | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005445-32 | Sponsor Protocol Number: LA-II-02 | Start Date*: 2016-06-24 | ||||||||||||||||
Sponsor Name:BIOrest, Ltd. | ||||||||||||||||||
Full Title: The BLADE-PCI Trial (PHASE IIB LIPOSOMAL ALENDRONATE STUDY): Biorest Liposomal Alendronate Administration for Diabetic Patients Undergoing Drug-Eluting Stent Percutaneous Coronary Intervention | ||||||||||||||||||
Medical condition: PCI (percutaneous coronary intervention) for angina, silent ischemia or non-STEMI in patients with diabetes mellitus. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003625-42 | Sponsor Protocol Number: GS-US-342-4062 | Start Date*: 2017-03-24 | ||||||||||||||||
Sponsor Name:Gilead Sciences, Inc. | ||||||||||||||||||
Full Title: A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir for 12 Weeks in Subjects with Chronic HCV Infection Who are on Dialysis for End Stage Renal Di... | ||||||||||||||||||
Medical condition: Chronic Hepatitis C virus infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-003141-28 | Sponsor Protocol Number: CCR4500 | Start Date*: 2017-04-04 |
Sponsor Name:The Institute of Cancer Research | ||
Full Title: ACE: Proof of concept Phase I/II trial of the CXCR2 antagonist AZD5069, administered in combination with enzalutamide, in patients with metastatic castration resistant prostate cancer(mCRPC) | ||
Medical condition: Metastatic castration resistant prostate cancer | ||
Disease: | ||
Population Age: | Gender: Male | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004459-65 | Sponsor Protocol Number: SEP-RES-2016-01 | Start Date*: 2017-03-20 | |||||||||||
Sponsor Name:Respira. Fundación Española del Pulmón (SEPAR) | |||||||||||||
Full Title: Reslizumab in patients with severe asthma who failed to respond to omalizumab: a pilot study | |||||||||||||
Medical condition: Severe asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000308-28 | Sponsor Protocol Number: ICL670F1102 | Start Date*: 2016-03-09 |
Sponsor Name:Novartis | ||
Full Title: A randomized, open label, six sequences, cross-over study in healthy Japanese subjects to evaluate the pharmacokinetic comparability of deferasirox granule formulation with the reference dispersibl... | ||
Medical condition: Healthy adult subjects | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
